Join our daily newsletter At The Bell to receive exclusive market insights
- Race Oncology (RAC) is set to expand its BISECT cancer trial for its Zantrene product to include five additional trial sites in Spain and Italy
- With the extra trial sites, Race has signed a new clinical support agreement with Parexel International to support the necessary additional monitoring activities
- The BISECT trial is testing Race’s Zantrene drug on extramedullary Acute Myeloid Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS)
- Race is expecting the overall study to cost between $7.7 million to $15.4 million, depending on the location and number of patients that are enrolled
- Shares in Race Oncology are up 3.66 per cent and trading at $1.70 per share at 12:55 pm AEST
Race Oncology (RAC) has agreed to expand its BISECT cancer trial for its lead Zantrene product to include five additional trial sites in Spain and Italy.
With the extra trial sites, Race has signed a new clinical support agreement with a global research organisation, Parexel International, to support additional necessary trial monitoring activities.
The BISECT trial is testing Zantrene drug on extramedullary Acute Myeloid
Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS).
Race Chief Medical Officer David Fuller said the company was pleased with the strong support for its BISECT trial from European haematologists.
“These clinicians identify a significant unmet need for the treatment of EMD AML and MDS and want to be actively involved in EMD clinical research,” Dr Fuller said.
“We look forward to activating these sites once we have cleared the necessary European Regulatory and Ethics approval process.”
EMD AML is when leukaemia cells spread from bone marrow and form a solid tumour in other tissues like the skin, breast, brain, or other organs. MDS are a group of blood cancers that all affect the production of normal blood cells in the bone marrow.
The company commenced patient recruitment in April at the Calvary Mater Hospital Newcastle.
Race is expecting the overall study to cost between $7.7 million to $15.4 million, depending on the location and number of patients that are enrolled and screened in the trial.
Shares in Race Oncology were up 3.66 per cent and trading at $1.70 per share at 12:55 pm AEST.
